Strategies for biomarker discovery in fibrotic disease

The discovery and development of biomarkers for fibrotic diseases have potential utility in clinical decision-making as well as in pharmaceutical research and development. This review describes strategies for identifying diagnostic, prognostic and theranostic biomarkers. A range of technologies and...

Full description

Saved in:
Bibliographic Details
Published in:Biochimica et biophysica acta 2013-07, Vol.1832 (7), p.1079-1087
Main Authors: Marshall, Richard P., Simpson, Juliet K., Lukey, Pauline T.
Format: Article
Language:English
Subjects:
Biomarker discovery
Biomarkers
Biomedical Research
Diagnostic
Drug discovery
Fibrosis
Humans
Prognostic
Proteomics
Theranostic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The discovery and development of biomarkers for fibrotic diseases have potential utility in clinical decision-making as well as in pharmaceutical research and development. This review describes strategies for identifying diagnostic, prognostic and theranostic biomarkers. A range of technologies and platforms for biomarker discovery are highlighted, including several with specific relevance for fibrosis. Some challenges specific to fibrotic diseases are outlined including; benchmarking biomarkers against imperfect clinical measures of fibrosis, the complexity resulting from diverse aetiologies and target organs, and the availability of samples (including biopsy) from well-characterised patients with fibrotic disease. To overcome these challenges collaboration amongst clinical specialities as well as between academia and industry is essential. This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease. ► Fibrosis is a core process in a number of chronic progressive diseases with a variety of aetiologies. ► The dynamic nature of extracellular matrix deposition lends itself to biomarker discovery. ► Diagnostic, prognostic and theranostic markers are required. ► Platform technologies as well as statistical approaches to biomarker discovery are discussed. ► Interdisciplinary as a well as public/private collaborations will be required for success.
ISSN:0925-4439
0006-3002
1879-260X
DOI:10.1016/j.bbadis.2013.01.018